Week brief · November 16 to 22, 2026
Biotech news, week of November 16, 2026
In the week of November 16 to 22, 2026 the Biotech desk recorded 9 news events on 4 days. Clinical trial led with 3.
- news events9
- outlet reports17
- days with news4
- carried by 5+ outlets0
The most covered stories of the week
- Nov 16 Wegovy cut BMI 13.5% vs placebo in children ages 6 to 11 in phase III trial 2
- Nov 16 FDA approves Roche's oral SERD Wilserdly for ESR1-mutated breast cancer 2
- Nov 17 Isomorphic Labs raises $5bn Series C to scale preclinical AI pipeline 2
- Nov 17 fool.com: “Stock Market Today, Nov. 17: Nvidia Slides Ahead of Earnings but Soars in After Hours Trading” 2
- Nov 18 Sanofi's venglustat wins FDA approval in type 3 Gaucher disease 2
- Nov 20 Biotech legal teams shift toward commercialization work as listings rebound 2
- Nov 20 Petition seeks FDA definition change covering D-tagatose 2
- Nov 17 techcrunch.com: “Science Corporation’s brain tech is worth $3.5 billion after new funding” 1
Monday, November 16, 2026
-
01
Wegovy cut BMI 13.5% vs placebo in children ages 6 to 11 in phase III trial
Machine summary Novo Nordisk reported full phase III STEP Young results showing semaglutide (Wegovy) reduced mean BMI 13.5% at week 68 versus a 2.7% increase on placebo in 167 children ages 6 to under 12 with obesity, a between-group difference of 16.2 percentage points. At week 104 the difference was 17.8 percentage points, and 38% of treated children fell below the obesity threshold by week 68 versus 2% on placebo. The findings were presented at ObesityWeek and published simultaneously in the New England Journal of Medicine.
- At week 68 of the phase III STEP Young trial, mean BMI fell 13.5% with semaglutide versus a 2.7% increase on placebo, an estimated between-group difference of 16.2 percentage points (95% CI -19.4 to -12.9, P<0.001) including all randomized participants
- On an analysis counting only children who stayed on treatment, semaglutide lowered BMI 17.4% versus a 2.2% rise on placebo at week 68, an estimated difference of 19.7 percentage points, CNBC reported
- At week 104, mean BMI change reached -9.4% in the semaglutide group and +8.4% with placebo, for a between-group gap of 17.8 percentage points (95% CI -22.2 to -13.3).
- 38% of children on semaglutide dropped below the obesity threshold (95th percentile for age and sex) by week 68 versus 2% on placebo; at week 104 the figures were 33% and 2%
- All 167 children in the trial received lifestyle modifications including a reduced-calorie diet and increased physical activity; 85% began with moderate to severe obesity
Reported by CNBC and MedPage Today.
- Novo Nordisk
- Wegovy
- New England Journal of Medicine
- ObesityWeek
- STEP Young
-
02
FDA approves Roche's oral SERD Wilserdly for ESR1-mutated breast cancer
Machine summary The FDA approved Roche's oral selective estrogen receptor degrader giredestrant (Wilserdly) in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The agency also authorized a blood test to identify eligible patients, and Roche stated the recommended dose is 30 milligrams once a day.
- Roche said the phase III evERA trial showed a 62% reduction in the risk of progression or death versus standard endocrine therapy plus everolimus, with a stratified hazard ratio of 0.38
- Additionally, a blood-based test to identify patients who qualify for treatment was authorized by the FDA, while Roche indicated that the recommended daily dose of giredestrant is 30 milligrams taken once a day.
- According to Roche, ESR1 mutations arise among up to 40% of patients whose metastatic breast cancer is hormone receptor-positive, and may indicate resistance to standard treatments.
Reported by Inquisitr Health & and MedPage Today.
- Roche
- evERA trial
- everolimus
- Wilserdly (giredestrant)
Tuesday, November 17, 2026
-
03
Isomorphic Labs raises $5bn Series C to scale preclinical AI pipeline
Machine summary Isomorphic Labs announced a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other new investors joining and continued investment from Alphabet. The company said IsoDDE unifies foundational simulation AI models across multiple therapeutic areas and drug modalities, and reported positive preclinical results in internal oncology and immunology programs and with partners.
- Isomorphic Labs announced a $5 billion Series C financing round on 17 November 2026, according to the company's announcement.
- The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and several other new investors participating and Alphabet continuing to invest, the company said.
- Every current backer took part, the company said, listing the UK Sovereign AI Fund alongside Thrive Capital, MGX, GV, CapitalG, plus Temasek.
- The company said IsoDDE, its drug design engine, unifies foundational simulation AI models working across multiple therapeutic areas and drug modalities.
Reported by Pr Newswire Uk and Sifted.
-
04
Coverage recordfool.com: “Stock Market Today, Nov. 17: Nvidia Slides Ahead of Earnings but Soars in After Hours Trading”
Reports ran from 22:23 UTC on Nov 17 to 21:57 UTC on Nov 19.
The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).
Reported by fool.com and wired.com.
- NVIDIA
- Recursion Pharmaceuticals
- REC-4881
-
05
Coverage recordtechcrunch.com: “Science Corporation’s brain tech is worth $3.5 billion after new funding”
The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).
Reported by techcrunch.com.
Wednesday, November 18, 2026
-
06
Sanofi's venglustat wins FDA approval in type 3 Gaucher disease
Machine summary The FDA has cleared Sanofi's venglustat (Infilbray) as the first therapy for type 3 Gaucher disease's neurologic symptoms, in adults and children whose weight is at least 15 kg, MedPage Today and Seeking Alpha report. The phase III LEAP2MONO trial compared daily oral venglustat with intravenous imiglucerase in 43 patients aged 12 and older and reported significant improvement on a global neurologic endpoint test at 52 weeks (P=0.0137).
- Approval was based on the phase III LEAP2MONO trial in 43 patients aged 12 and older who had already stabilized their systemic disease on enzyme replacement therapy, MedPage Today reported.
- MedPage Today reports that, over 52 weeks, a worldwide trial measuring several neurologic endpoints found significant gains in ataxia-related symptoms and in cognitive function, with P=0.0137.
- Unlike the intravenous agent imiglucerase (Cerezyme), which serves as the comparator in LEAP2MONO, Venglustat is an orally administered inhibitor of glucosylceramide synthase engineered to pass through the blood-brain barrier.
- Gastrointestinal effects were among the most frequently reported side effects, MedPage Today reported.
- Seeking Alpha reported the approval as a Sanofi win, identifying Sanofi as the company behind venglustat.
Reported by Seeking Alpha and MedPage Today.
- Sanofi
- LEAP2MONO
- Venglustat (Infilbray)
- Imiglucerase (Cerezyme)
Friday, November 20, 2026
-
07
Biotech legal teams shift toward commercialization work as listings rebound
Machine summary The article describes legal teams increasingly involved in launch activities, regulatory requirements, pricing and market access.
- After a biotech boom in 2020-2021, tighter funding, layoffs and pipeline failures led companies to preserve cash and hire much more selectively, the article states.
- The article reports that businesses have shifted their attention back toward expansion and capital spending, while initial public offering activity has started to recover.
- Nearly 40% of pharmaceutical respondents, according to a survey referenced in the piece, anticipate shifting toward direct-to-patient access and fulfillment models over the coming 24 to 36 months.
- The article reports that demand has risen for brand lawyers, commercial lawyers, market access lawyers and healthcare compliance specialists.
- Employers are competing for a small pool of specialized talent and are rethinking the experience, qualifications and flexibility they require from candidates, per the article.
Reported by The National Law Review and National Law Review.
-
08
Petition seeks FDA definition change covering D-tagatose
Machine summary A petition filed by Bonumose on October 23, 2026 asks FDA to amend the dietary fiber definition to include non-digestible carbohydrates of fewer than three monomeric units and to permit D-tagatose to be declared as dietary fiber, the National Law Review reported. The company presents evidence of D-tagatose's claimed beneficial health effects and argues the unit-count qualifier reflects a policy choice. FDA denied a similar petition from Bonumose in 2021.
- On October 23, 2026, Bonumose, Inc. petitioned FDA to amend the dietary fiber definition to cover non-digestible carbohydrates with fewer than three monomeric units, the National Law Review reported.
- The petition also asks FDA to permit D-tagatose to be declared as dietary fiber based on what the company claims are beneficial physiological effects.
- FDA's current definition at 21 CFR 101.9(c)(6)(i) covers isolated or synthetic non-digestible carbohydrates "with 3 or more monomeric units" that FDA determines have beneficial physiological effects.
- D-tagatose is described in the report as a largely non-digestible monosaccharide, a single monomeric unit, outside the current unit-count threshold.
- FDA denied a similar Bonumose petition in 2021, concluding the "3 or more monomeric units" qualifier was "consistent with international scientific consensus."
Reported by The National Law Review and National Law Review.
- National Law Review
- 21 CFR 101.9(c)(6)(i)
- D-Tagatose
- Bonumose, Inc.
More events reported
No summary of ours and no outlet headline passed our automated checks for these, which says nothing about the events (how they work); the outlets and their reports are linked.
Friday, November 20, 2026
- · 2 outlets Ktul, KOKI FOX 23
Summaries and key facts are machine summaries of the reports linked with them; outlets, times and counts come from those reports. How a rundown is built.
What kind of news was it?
Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).